BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25922348)

  • 1. Challenging the Inevitability of Prostate Enlargement: Low Levels of Benign Prostatic Hyperplasia Among Tsimane Forager-Horticulturalists.
    Trumble BC; Stieglitz J; Eid Rodriguez D; Cortez Linares E; Kaplan HS; Gurven MD
    J Gerontol A Biol Sci Med Sci; 2015 Oct; 70(10):1262-8. PubMed ID: 25922348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men.
    Liu CC; Huang SP; Li WM; Wang CJ; Chou YH; Li CC; Huang CH; Wu WJ
    Urology; 2007 Oct; 70(4):677-80. PubMed ID: 17991536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of androgen deficiency and replacement on prostate zonal volumes.
    Jin B; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):437-45. PubMed ID: 11318778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
    Marberger M; Roehrborn CG; Marks LS; Wilson T; Rittmaster RS
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1323-8. PubMed ID: 16434455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Kristal AR; Schenk JM; Song Y; Arnold KB; Neuhouser ML; Goodman PJ; Lin DW; Stanczyk FZ; Thompson IM
    Am J Epidemiol; 2008 Dec; 168(12):1416-24. PubMed ID: 18945688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone concentration, metabolic disorders and immunoexpression of androgen and estrogen-alpha receptors in men with benign prostatic hyperplasia and testosterone deficiency syndrome.
    Ryl A; Rotter I; Slojewski M; Dolegowska B; Grabowska M; Baranowska-Bosiacka I; Laszczynska M
    Folia Histochem Cytobiol; 2015; 53(3):227-35. PubMed ID: 26400665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
    Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
    Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of Prostate Specific Antigen and Testosterone Hormone Levels in Patients of Benign Prostatic Hyperplasia in Khartoum State-Sudan.
    A M Alameen A; A M Osman T; A Elissidig S; Atif M
    Pak J Biol Sci; 2020 Jan; 23(11):1431-1435. PubMed ID: 33274871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum sex hormones and measures of benign prostatic hyperplasia.
    Roberts RO; Jacobson DJ; Rhodes T; Klee GG; Leiber MM; Jacobsen SJ
    Prostate; 2004 Oct; 61(2):124-31. PubMed ID: 15305335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between selected hormone and protein levels in serum and prostate tissue homogenates in men with benign prostatic hyperplasia and metabolic disorders.
    Grzesiak K; Rył A; Baranowska-Bosiacka I; Rotter I; Dołęgowska B; Słojewski M; Sipak-Szmigiel O; Ratajczak W; Lubkowska A; Metryka E; Piasecka M; Laszczyńska M
    Clin Interv Aging; 2018; 13():1375-1382. PubMed ID: 30122909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the Serum Prostatic Biomarkers During the Treatment of Benign Prostatic Hyperplasia with a 5alpha-reductase Inhibitor: Finasteride.
    Golchin-Rad K; Mogheiseh A; Nazifi S; Ahrari Khafi MS; Derakhshandeh N; Abbaszadeh-Hasiri M
    Top Companion Anim Med; 2020 Mar; 38():100405. PubMed ID: 32115076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer.
    Rannikko S; Adlercreutz H
    Prostate; 1983; 4(3):223-9. PubMed ID: 6189106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ageratum conyzoides L. inhibits 5-alpha-reductase gene expression in human prostate cells and reduces symptoms of benign prostatic hypertrophy in otherwise healthy men in a double blind randomized placebo controlled clinical study.
    Detering M; Steels E; Koyyalamudi SR; Allifranchini E; Bocchietto E; Vitetta L
    Biofactors; 2017 Nov; 43(6):789-800. PubMed ID: 29048765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced circulating androgen bioactivity in patients with prostate cancer.
    Raivio T; Santti H; Schatzl G; Gsur A; Haidinger G; Palvimo JJ; Jänne OA; Madersbacher S
    Prostate; 2003 May; 55(3):194-8. PubMed ID: 12692785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum concentrations of sex hormones in men with severe lower urinary tract symptoms and benign prostatic hyperplasia.
    Tan MO; Karabiyik I; Uygur MC; Diker Y; Erol D
    Int Urol Nephrol; 2003; 35(3):357-63. PubMed ID: 15160539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia.
    Khan S; Wolin KY; Pakpahan R; Grubb RL; Colditz GA; Ragard L; Mabie J; Breyer BN; Andriole GL; Sutcliffe S
    BMC Urol; 2021 Mar; 21(1):47. PubMed ID: 33773592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community-based research on the benign prostatic hyperplasia prevalence rate in Korean rural area.
    Goh HJ; Kim SA; Nam JW; Choi BY; Moon HS
    Korean J Urol; 2015 Jan; 56(1):68-75. PubMed ID: 25598939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men.
    Lee JH; Kim Y; Park YW; Lee DG
    J Sex Med; 2014 May; 11(5):1309-15. PubMed ID: 24612680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer.
    Gonzalez-Barcena D; Vadillo-Buenfil M; Gomez-Orta F; Fuentes Garcia M; Cardenas-Cornejo I; Graef-Sanchez A; Comaru-Schally AM; Schally AV
    Prostate; 1994; 24(2):84-92. PubMed ID: 7508623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.